Novocure Reports Third Quarter 2015 Operating and Financial Results

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors, today reported operating and financial results for the three and nine months ended September 30, 2015. “The last few months were marked by a number of significant milestones. Most notably, on October 5, we received FDA approval …

NovoCure Limited Announces Closing of Partial Exercise of IPO Over-Allotment Option

ST. HELIER, Jersey–(BUSINESS WIRE)–NovoCure Limited (NASDAQ: NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors, announced the closing today of a partial exercise of the over-allotment option by the underwriters of its previously announced initial public offering in the amount of an additional 376,195 ordinary shares at IPO price. There remain …

Novocure to Offer On Demand Optune Certification Training for the Radiation Oncology Community at ASTRO 2015

Optune is the first FDA-approved therapy in more than a decade to demonstrate statistically significant extension of survival in newly diagnosed glioblastoma patients ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors, announced today it will offer on demand Optune certification training for the radiation oncology …

Novocure to Report Third Quarter 2015 Financial Results on Monday, October 26

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors, announced today that it will report financial results for the third quarter of 2015 on Monday, October 26, 2015 after the close of U.S.-based financial markets. Following the announcement, Novocure management will host a conference call and …

ADDING MULTIMEDIA FDA Approves Optune in Combination with Temozolomide for the Treatment of Newly Diagnosed Glioblastoma

Optune is the first FDA-approved therapy in more than a decade to demonstrate statistically significant extension of survival in newly diagnosed glioblastoma patients ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) has approved Optune in combination with temozolomide for the treatment of adult patients with newly diagnosed …

NovoCure Limited Announces Closing of Initial Public Offering

ST. HELIER, Jersey–(BUSINESS WIRE)–NovoCure Limited (NASDAQ: NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors, announced today the closing of its initial public offering of 7,500,000 ordinary shares at a price to the public of $22 per share. In addition, the underwriters for the offering have a 30-day option, commencing on …

Novocure Announces CE Mark and First Patient Use of Second Generation Optune System

The newly designed, second generation Optune system incorporates state of the art digital technology and is more than 50% lighter and 50% smaller than the first generation system ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ:NVCR), a commercial stage oncology company, announced today the placement of the CE mark on, and first patient use of, the newly designed …

NovoCure Limited Announces Launch of Initial Public Offering

ST. HELIER, Jersey–(BUSINESS WIRE)–NovoCure Limited, a commercial stage oncology company pioneering a novel therapy for solid tumors, announced today the launch of its initial public offering of 12,500,000 shares of its common stock, including 7,500,000 shares to be sold by NovoCure Limited and 5,000,000 shares to be sold by selling shareholders. The initial public offer …